



Laura Johnston

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) at the Stanford University Medical Center

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICES

- **Blood and Marrow Transplant Clinic**

875 Blake Wilbur Dr Clinic F

MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 498-6919

ACADEMIC CONTACT INFORMATION

- **Administrative Associate**

Janice Smith - Administrative Associate

Email janices1@stanford.edu

Tel 650.724.4155

Bio

BIO

Dr. Laura Johnston currently serves as the Clinical Director and Clinic Chief of the Blood & Marrow Transplantation Division and specializes in Graft Versus Host Disease (GVHD), exploring prevention and treatment of acute and chronic GVHD via clinical trials. She conducts and develops clinical research trials in allogeneic and autologous hematopoietic cell transplantation (HCT) for hematologic malignancies: acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), myeloproliferative disease, non-Hodgkin lymphoma (NHL), Hodgkin disease, myelodysplasia and aplastic anemia.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Hematology
- Blood and Marrow Transplantation
- Graft-Versus-Host Disease
- Hematology

ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Clinical Director, Division of Blood and Marrow Transplantation Stanford University Medical Center, (2009- present)
- BMT Cancer Care Program Physical Lead, Stanford Cancer Institute, (2010- present)
- Clinic Chief, Division of Blood and Marrow Transplantation Stanford University Medical Center, (2001- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, BMT Inpatient Utilization Task Force (2012 - present)

- Chairperson, BMT Review Committee (2011 - present)
- Member, Department of Medicine Quality Council (2011 - present)
- Member, Clinically Active Physician Council (2010 - present)
- Member, Kaiser/SHC BMT Strategic Alliance for Adult Blood and Marrow/Peripheral Stem Cell Transplantation Work Group (2010 - present)
- Preceptor, Ambulatory Medicine Clerkship Med 313 students (2009 - present)
- Mentor, Stanford Immersion in Medicine Program (2008 - present)
- Member, American Society of Blood and Marrow Transplantation (1996 - present)
- Member, American Society of Clinical Oncology (1992 - present)
- Member, American Society of Hematology (1992 - present)

PROFESSIONAL EDUCATION

- Medical Education: University of Minnesota School of Medicine Registrar (1989) MN
- Board Certification: Hematology, American Board of Internal Medicine (1997)
- Fellowship: UCSF Medical Center (1995) CA
- Residency: UCSF Medical Center (1992) CA
- Internship: UCSF Medical Center (1990) CA
- BS, University of MN , Microbiology (1982)
- MD, University of MN , Medicine (1989)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

I conduct and develop clinical research trials in allogeneic and autologous hematopoietic cell transplantation (HCT) for hematologic malignancies: acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), myeloproliferative disease, non-Hodgkin lymphoma (NHL), Hodgkin disease, myelodysplasia and aplastic anemia.

A specific interest is graft versus host disease (GVHD), exploring prevention and treatment of acute and chronic GVHD via clinical trials. The objectives of the GVHD trials are to reduce the incidence of GVHD, successfully treat acute and chronic GVHD, identify modalities or agents with more tolerable toxicity profiles and ultimately improve morbidity and mortality of affected patients. To this end, I have established a chronic GVHD clinic within the Stanford BMT division which aids in prospectively identifying appropriate patients for clinical trials. The chronic GVHD clinic allows comprehensive evaluation and treatment for allogeneic BMT patients with new or progressive CGVHD. Through a multidisciplinary approach with my interested colleagues, I hope to impact the formidable effects GVHD has on the quality of life of the post-allogeneic transplant patient.

Other interests include unrelated donor HCT exploring alternate preparative regimens or graft sources as well as HLA typing.

CLINICAL TRIALS

- Bone Marrow Grafting for Leukemia and Lymphoma, Recruiting

- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Recruiting
- Composite Health Assessment Risk Model (CHARM) for Older Adults, Recruiting
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant, Recruiting
- Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases, Recruiting
- MAGE A10####T for Advanced NSCLC, Recruiting
- Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries, Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors, Recruiting
- 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL, Not Recruiting
- A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease, Not Recruiting
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial), Not Recruiting
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease, Not Recruiting
- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML), Not Recruiting
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802), Not Recruiting
- Allo BMT in Advanced Leukemia or High Grade Lymphoma, Not Recruiting
- Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102), Not Recruiting
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML, Not Recruiting
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML), Not Recruiting
- Allogeneic Transplantation From Related Haploidentical Donors, Not Recruiting
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies, Not Recruiting
- Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission, Not Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma, Not Recruiting
- Autologous Stem Cell Rescue for Primary Amyloidosis, Not Recruiting
- Blood and Marrow Transplant Clinical Research Network, Not Recruiting
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801), Not Recruiting
- Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder, Not Recruiting
- Defibrotide for Patients With Hepatic Venooclusive Disease: A Treatment IND Study, Not Recruiting
- Defibrotide for the Treatment of Severe Hepatic Venooclusive Disease in Hematopoietic Stem Cell Transplant Patients, Not Recruiting
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Double Cord Versus Haploidentical (BMT CTN 1101), Not Recruiting
- Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma, Not Recruiting
- Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies, Not Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease, Not Recruiting
- Haploid Allogeneic Transplant Using the CliniMACS System, Not Recruiting
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma, Not Recruiting

- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma, Not Recruiting
- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma, Not Recruiting
- Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD), Not Recruiting
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease, Not Recruiting
- Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation, Not Recruiting
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT), Not Recruiting
- Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma, Not Recruiting
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML, Not Recruiting
- Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders, Not Recruiting
- Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma, Not Recruiting
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201), Not Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma, Not Recruiting
- Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD, Not Recruiting
- Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease, Not Recruiting
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell, Not Recruiting
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT, Not Recruiting
- Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG, Not Recruiting
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD, Not Recruiting
- Phase II Early Behavioral Intervention in BMT w/ Sleep Disturbance-Assess QOL+Fatigue+Cognitive f(x), Not Recruiting
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders, Not Recruiting
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies, Not Recruiting
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients, Not Recruiting
- Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer, Not Recruiting
- Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies, Not Recruiting
- Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT, Not Recruiting
- Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant, Not Recruiting
- Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease, Not Recruiting
- Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease, Not Recruiting
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402), Not Recruiting
- Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors, Not Recruiting
- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702), Not Recruiting
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease, Not Recruiting
- Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD), Not Recruiting
- Targeted Therapy of Bronchiolitis Obliterans Syndrome, Not Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD, Not Recruiting
- Transplantation for Patients With Chronic Lymphocytic Leukemia, Not Recruiting

- Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation, Not Recruiting

Publications

PUBLICATIONS

- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
2021
- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
2021
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143–55
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z. n., Spiegel, J. Y., Craig, J. n., Claire, G. K., Frank, M. J., Muffly, L. n., Shiraz, P. n., Meyer, E. n., Arai, S. n., Brown, et al
2021; 5 (1): 143–55
- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
2020
- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
ELSEVIER SCIENCE INC.2020: S106
- **Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool**
Mishra, A., Preussler, J. M., Al-Mansour, Z., Bachanova, V., Bhatt, V., Bredeson, C., Chhabra, S., D'Souza, A., Dahi, P. B., DeFilipp, Z., Gowda, L., Hacker, E., Hashmi, et al
ELSEVIER SCIENCE INC.2020: S45–S46
- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
2020
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al

2020

- **Machine learning algorithms to differentiate among pulmonary complications after hematopoietic cell transplant.** *Chest*
Sharifi, H. n., Lai, Y. K., Guo, H. n., Hoppenfeld, M. n., Guenther, Z. D., Johnston, L. n., Brondstetter, T. n., Chhatwani, L. n., Nicolls, M. R., Hsu, J. L.
2020
- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al
2020; 4 (18): 4474–82
- **Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)** *BONE MARROW TRANSPLANTATION*
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., Chabannon, C., Perales, M. A., Hudecek, et al
2019; 54 (11): 1868–80
- **HLA Class II Donor-Specific Antibody Desensitization with Nonleukoreduced Irradiated Whole Blood Pretransplant**
Jacob, R., Tho Pham, Vina, M., Zhang, M., Johnston, L., Hussain, M., Pandey, S.
WILEY.2019: 94A
- **Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
DeFilipp, Z., Advani, A. S., Bachanova, V., Cassaday, R. D., Deangelo, D. J., Kebriaei, P., Rowe, J. M., Seftel, M. D., Stock, W., Tallman, M. S., Fanning, S., Inamoto, Y., Kansagra, et al
2019
- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
2019; 4 (10)
- **Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).** *Bone marrow transplantation*
Kansagra, A. J., Frey, N. V., Bar, M. n., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., Chabannon, C. n., Perales, M. A., Hudecek, et al
2019
- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
2019; 3 (16): 2454–64
- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.** *JCI insight*
Meyer, E. H., Laport, G. n., Xie, B. J., MacDonald, K. n., Heydari, K. n., Sahaf, B. n., Tang, S. W., Baker, J. n., Armstrong, R. n., Tate, K. n., Tadisco, C. n., Arai, S. n., Johnston, et al
2019; 4 (10)
- **ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Sauter, C. S., DeFilipp, Z., Inamoto, Y., Johnston, L., Nagler, A., Savani, B. N., Carpenter, P. A., Perales, M.
2018
- **Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., Chabannon, C., Perales, M. A., Hudecek, et al
2018

- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2018
- **Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
AMER SOC HEMATOLOGY.2018
- **Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Gooptu, M., Kim, H. T., Chen, Y., Rybka, W., Artz, A., Boyer, M., Johnston, L., McGuirk, J., Shea, T. C., Jagasia, M., Shaughnessy, P. J., Reynolds, C. G., Fields, et al
2018; 24 (11): 2216–23
- **A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801** *HAEMATOLOGICA*
Carpenter, P. A., Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolanos-Meade, J., Sarantopoulos, S., Alousi, A. M., Abhyankar, S., Waller, E. K., Mendizabal, et al
2018; 103 (11): 1915–24
- **ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Hashmi, S. K., Lee, S. J., Savani, B. N., Burns, L., Wingard, J. R., Perales, M., Palmer, J., Chow, E., Meyer, E., Marks, D., Mohty, M., Inamoto, Y., Rodriguez, et al
2018; 24 (6): 1119–24
- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
2018; 2 (6): 681–90
- **Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells**
Meyer, E., Laport, G. G., Tantsura, I., Tang, S., Sahaf, B., Rangarajan, K., Armstrong, R., Tate, K., Tudisco, C., Sheehan, K., Arai, S., Johnston, L., Muffly, et al
ELSEVIER SCIENCE INC.2018: S145
- **Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., Beumer, J. H., Qiu, J., Cerda, K., Le, R., Otani, J. M., Liu, H., Ross, et al
2018; 24 (2): 373–80
- **Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation** *Oncology nursing forum*
Scheiber, C. n., Johnston, L. n., Packer, M. n., Gevirtz, R. n., Edwards, K. S., Palesh, O. n.
2018; 45 (2): 250–59
- **Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Soiffer, R. J., Kim, H. T., McGuirk, J., Horwitz, M. E., Johnston, L., Patnaik, M. M., Rybka, W., Artz, A., Porter, D. L., Shea, T. C., Boyer, M. W., Maziarz, R. T., Shaughnessy, et al
2017: JCO2017758177
- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
2017; 23 (10): 1744–48
- **Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia** *BLOOD*
Carpenter, P. A., Johnston, L., Fernandez, H. F., Radich, J. P., Mauro, M. J., Flowers, M. D., Martin, P. J., Gooley, T. A.
2017; 130 (9): 1170–72

- **Increased Foxp3(+)/Helios(+) Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Chen, Y., Efebera, Y. A., Johnston, L., Ball, E. D., Avigan, D., Lekakis, L. J., Bachier, C. R., Martin, P., Duramad, O., Ishii, Y., Han, S., Jung, Y., Lee, et al
2017; 23 (4): 625-634
- **Integrating cancer survivorship care into allogeneic BMT recovery.**
Bugos, K., Stenger, S., Smith, A., Johnston, L., Gross, M., Knight, G., Lambert, S., Muffly, L. S.
AMER SOC CLINICAL ONCOLOGY.2017
- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
2017; 1 (17): 1347–57
- **Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center** *Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center*
Porter, J. B.
2017; 13 (8): e673-e682
- **A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)**
Soiffer, R. J., Kim, H. T., McGuirk, J., Horwitz, M. E., Johnston, L., Patnaik, M. M., Rybka, W., Artz, A., Porter, D. L., Shea, T. C., Boyer, M. W., Maziarz, R. T., Jagasia, et al
AMER SOC HEMATOLOGY.2016
- **A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease**
Johnston, L., Armstrong, R., Baker, J., Sahaf, B., Otani, J., Tate, K., Tudisco, C., Sheehan, K., Meyer, E., Miklos, D., Negrin, R. S.
AMER SOC HEMATOLOGY.2016
- **Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation**
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
AMER SOC HEMATOLOGY.2016
- **Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors**
Spinner, M. A., Vina, M., Elder, L., Arai, S., Johnston, L., Meyer, E., Miklos, D., Muffly, L., Negrin, R. S., Shizuru, J., Weng, W., Laport, G. G., Strober, et al
AMER SOC HEMATOLOGY.2016
- **Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant** *ANNALS OF THE AMERICAN THORACIC SOCIETY*
Cheng, G., Storer, B., Chien, J. W., Jagasia, M., Hubbard, J. J., Burns, L., Ho, V. T., Pidala, J., Palmer, J., Johnston, L., Mayer, S., Crothers, K., Pusic, et al
2016; 13 (11): 1932–39
- **Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Williams, K. M., Cheng, G., Pusic, I., Jagasia, M., Burns, L., Ho, V. T., Pidala, J., Palmer, J., Johnston, L., Mayer, S., Chien, J. W., Jacobsohn, D. A., Pavletic, et al
2016; 22 (4): 710-716
- **Central Nervous System Involvement of Chronic Graft Versus Host Disease**
Neppalli, A., Johnston, L.
ELSEVIER SCIENCE INC.2016: S407
- **Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network**
Carpenter, P. A., Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolanos-Meade, J., Alousi, A. M., Horowitz, M. M., Abhyankar, S., Waller, E. K., Mendizabal, et al
ELSEVIER SCIENCE INC.2016: S50–S52
- **Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin**

- Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W., Arai, S., Johnston, L., Laport, G. G., Shizuru, J. A., Negrin, R., Strober, S., Lowsky, et al
ELSEVIER SCIENCE INC.2016: S204–S205
- **Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Williams, K. M., Cheng, G. S., Pusic, I. n., Jagasia, M. n., Burns, L. n., Ho, V. T., Pidala, J. n., Palmer, J. n., Johnston, L. n., Mayer, S. n., Chien, J. W., Jacobsohn, D. A., Pavletic, et al
2016; 22 (4): 710–16
 - **Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms**
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., Galvez, L., Armstrong, R., Sheehan, K., Lowsky, R., Arai, S., Johnston, L., Miklos, et al
AMER SOC HEMATOLOGY.2015
 - **Intensive Care Utilization for Hematopoietic Cell Transplant Recipients** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Jenkins, P., Johnston, L. J., Pickham, D., Chang, B., Rizk, N., Tierney, D. K.
2015; 21 (11): 2023-2027
 - **Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation** *ONCOLOGY NURSING FORUM*
Tierney, D. K., Palesh, O., Johnston, L.
2015; 42 (5): 488-497
 - **National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Carpenter, P. A., Kitko, C. L., Elad, S., Flowers, M. E., Gea-Banacloche, J. C., Halter, J. P., Hoodin, F., Johnston, L., Lawitschka, A., McDonald, G. B., Otipari, A. W., Savani, B. N., Schultz, et al
2015; 21 (7): 1167-1187
 - **A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph plus) Leukemias**
Carpenter, P. A., Johnston, L., Fernandez, H., Radich, J., Mauro, M. J., Flowers, M. D., Martin, P. J., Gooley, T.
ELSEVIER SCIENCE INC.2015: S274–S276
 - **Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation**
Williams, K. M., Cheng, G., Pusic, I., Jagasia, M. H., Burns, L. J., Ho, V. T., Pidala, J., Palmer, J., Johnston, L., Mayer, S., Jacobsohn, D. A., Martin, P. J., Storer, et al
ELSEVIER SCIENCE INC.2015: S61–S62
 - **BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial**
Cheng, G., Pusic, I., Jagasia, M. H., Burns, L. J., Ho, V. T., Pidala, J., Palmer, J., Johnston, L., Mayer, S., Chai, X., Lee, S. J., Williams, K. M.
ELSEVIER SCIENCE INC.2015: S172–S173
 - **Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.** *Bone marrow transplantation*
Percival, M. M., Medeiros, B. C., Tian, L. n., Robeson, S. n., Laport, G. G., Johnston, L. J., Shizuru, J. A., Miklos, D. B., Arai, S. n., Weng, W. K., Negrin, R. S., Lowsky, R. n.
2015
 - **Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)**
Weng, W., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Benjamin, J. E., Negrin, R. S., Reddy, S., Million, L., Hoppe, et al
AMER SOC HEMATOLOGY.2014
 - **Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Jim, H. S., Evans, B., Jeong, J. M., Gonzalez, B. D., Johnston, L., Nelson, A. M., Kesler, S., Phillips, K. M., Barata, A., Pidala, J., Palesh, O.
2014; 20 (10): 1465-1484

- **Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management.** *Biology of blood and marrow transplantation*
Jim, H. S., Evans, B., Jeong, J. M., Gonzalez, B. D., Johnston, L., Nelson, A. M., Kesler, S., Phillips, K. M., Barata, A., Pidala, J., Palesh, O.
2014; 20 (10): 1465-1484
- **Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT** *BLOOD*
Cutler, C., Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, et al
2014; 124 (8): 1372-1377
- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
2014; 20 (6): 837-843
- **Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience**
Wudhikarn, K., Lavori, P., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Hoppe, R. T., Benjamin, J., Meyer, E., Negrin, R., Weng, et al
ELSEVIER SCIENCE INC.2014: S164
- **Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study**
Jagasia, M. H., Chai, X., Pidala, J., Inamoto, Y., Arora, M., Cutler, C. S., Flowers, M. D., Johnston, L., Pavletic, S. Z., Lee, S. J.
ELSEVIER SCIENCE INC.2014: S269
- **Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation** *BMT Tandem Meetings*
Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J., Johnston, L., Arai, S., Weng, W., Negrin, R., Strober, et al
ELSEVIER SCIENCE INC.2013: S154-S155
- **TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN** *BMT Tandem Meetings*
Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R., Lowsky, R.
ELSEVIER SCIENCE INC.2013: S113-S114
- **Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Rose, J. A., Dunn, T. J., Liedtke, M., Elson, P., Kalaycio, M., Copelan, E., Sobecks, R., Sekeres, M. A., Hobson, S., Johnston, L., Tench, S., Cross, S., Advani, et al
AMER SOC HEMATOLOGY.2012
- **Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
AMER SOC HEMATOLOGY.2012
- **Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma** *BRITISH JOURNAL OF HAEMATOLOGY*
Minn, A. Y., Riedel, E., Halpern, J., Johnston, L. J., Horning, S. J., Hoppe, R. T., Goodman, K. A.
2012; 159 (3): 329-339
- **Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors** *NEW ENGLAND JOURNAL OF MEDICINE*
Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., Cutler, C. S., Westervelt, P., Woolfrey, A., Couban, S., Ehninger, G., Johnston, L., Maziarz, et al
2012; 367 (16): 1487-1496
- **Yield of Single versus Upper and Lower Endoscopic Biopsies in the Diagnosis of Gastrointestinal Graft-Versus-Host Disease in Patients with Prior Allogeneic Hematopoietic Stem Cell Transplantation**
Liu, A., Meyer, E., Johnston, L., Gerson, L.
NATURE PUBLISHING GROUP.2012: S731
- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*

- Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaeenman, J., Brown, et al
2012; 119 (25): 6145-6154
- **Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Sheehan, K., Lavori, P., Negrin, et al
2012; 47 (4): 581-588
 - **Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Mueller, A. M., Kohrt, H. E., Cha, S., Laport, G., Klein, J., Guardino, A. E., Johnston, L. J., Stockerl-Goldstein, K. E., Hanania, E., Juttner, C., Blume, K. G., Negrin, R. S., Weissman, et al
2012; 18 (1): 125-133
 - **A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. B., Arai, S., Johnston, L., Flowers, M. E., Beumer, J. H., Mendolsohn, J., Zhou, X., Perloff, S. H., Otani, J. M., Miklos, et al
AMER SOC HEMATOLOGY.2011: 866-67
 - **Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., Cutler, C. S., Westervelt, P., Woolfrey, A., Couban, S., Johnston, L., Maziarz, R. T., Pulsipher, et al
AMER SOC HEMATOLOGY.2011: 3-3
 - **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al
2011; 17 (11): 1679-1687
 - **A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRα antibodies** *BLOOD*
Chen, G. L., Arai, S., Flowers, M. E., Otani, J. M., Qiu, J., Cheng, E. C., McMillan, A., Johnston, L. J., Shizuru, J. A., Miklos, D. B.
2011; 118 (15): 4070-4078
 - **Rationale and Design of the Chronic GVHD Cohort Study: Improving Outcomes Assessment in Chronic GVHD** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Lee, S. J., Flowers, M. E., Martin, P. J., Carpenter, P., Hansen, J., Chai, X., Kurland, B., Storer, B., Arai, S., Johnston, L., Miklos, D., Weisdorf, D., Arora, et al
2011; 17 (8): 1114-1120
 - **Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Schaeenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., Wong, R. M., Ho, D. Y., Arai, S., Johnston, L., Brown, J. M.
2011; 17 (5): 693-702
 - **Long-term Clinical Course of Dry Eye in Patients With Chronic Graft-Versus-Host Disease Referred for Eye Examination** *CORNEA*
Sales, C. S., Johnston, L. J., Ta, C. N.
2011; 30 (2): 143-149
 - **Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY** *BONE MARROW TRANSPLANTATION*
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Blume, K., Negrin, R., Johnston, L.
2011; 46 (2): 192-199
 - **Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRα Antibodies Predict for Chronic Graft-Versus-Host Disease Development** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Chen, G. L., Arai, S., Flowers, M. E., Otani, J. M., Coram, M., McMillan, A., Shizuru, J. A., Johnston, L., Miklos, D.
AMER SOC HEMATOLOGY.2010: 958-58

- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al
2010; 16 (8): 1145-1154
- **Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure** *BONE MARROW TRANSPLANTATION*
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., Shizuru, J. A., JOHNSTON, L. J., Negrin, R. S., Lowsky, R., Laport, G. G.
2010; 45 (2): 303-309
- **A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFR α Antibody Analysis** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Chen, G. L., Arai, S., Flowers, M. E., Otani, J., Cheng, E. C., McMillan, A., Weng, W., Shizuru, J., Johnston, L., Miklos, D.
AMER SOC HEMATOLOGY.2009: 1281-81
- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al
2009; 114 (5): 1099-1109
- **Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease** *BLOOD*
Martin, P. J., Storer, B. E., Rowley, S. D., Flowers, M. E., Lee, S. J., Carpenter, P. A., Wingard, J. R., Shaughnessy, P. J., Devetten, M. P., Jagasia, M., Fay, J. W., Van Besien, K., Gupta, et al
2009; 113 (21): 5074-5082
- **High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience** *BONE MARROW TRANSPLANTATION*
Agarwal, R., Dvorak, C. C., Stockerl-Goldstein, K. E., Johnston, L., Srinivas, S.
2009; 43 (7): 547-552
- **Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hematopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Weng, W., Wong, R., Lavori, P., Blume, K., Negrin, R., Horning, et al
AMER SOC HEMATOLOGY.2008: 765-66
- **Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Schaenman, J., Vana, M. L., Rhee, C., Wong, J., Navato, S., Johnston, L. J., Wong, R. M., Ho, D. Y., Brown, J. C.
AMER SOC HEMATOLOGY.2008: 780-80
- **Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Arai, S., Sahaf, B., Jones, C., Zhender, J., Lowsky, R., Strober, S., Shizuru, J., Negrin, R., Johnston, L., Laport, G., Schaenman, J., Brown, J., Weng, et al
AMER SOC HEMATOLOGY.2008: 178-78
- **Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Johnston, L.
2008; 21 (2): 177-192
- **Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy** *49th Annual Meeting of the American-Society-of-Hematology*
Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., Lowsky, R., Miklos, D., Goldstein, K., Weng, W., Shizuru, J., Horning, S., Negrin, R.
AMER SOC HEMATOLOGY.2007: 179A-179A
- **The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia** *BLOOD*
Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., Appelbaum, F. R., Radich, J. P.
2007; 109 (4): 1782-1789
- **Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation.** *48th Annual Meeting of the American-Society-of-Hematology*

- Laport, G. G., Sheehan, K., Lowsky, R., Shizuru, J. A., Stockerl-Goldstein, K., Johnston, L. J., Miklos, D., Arai, S., Baker, J., Negrin, R. S.
AMER SOC HEMATOLOGY.2006: 126A–126A
- **Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD.** *48th Annual Meeting of the American-Society-of-Hematology*
Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., Shizuru, J., Negrin, R., Johnston, L., Laport, G., Goldstein, K., Brown, J. (., Miklos, et al
AMER SOC HEMATOLOGY.2006: 823A–823A
 - **Membranous glomerulonephritis and nephrotic syndrome as a late manifestation of chronic graft-versus-host reaction following allogeneic transplantation for hematologic malignancy.**
Ahmad, B., Stehr, B., Johnston, L., Smith, E., Nademane, A. P., Parker, P., Negrin, R., Forman, S. J.
AMER SOC HEMATOLOGY.2006: 819A–820A
 - **High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse large cell non-Hodgkin's lymphoma.** *48th Annual Meeting of the American-Society-of-Hematology*
Cao, T. M., Stockerl-Goldstein, K. E., Cao, P. D., Laport, G. G., Sheehan, K., Shizuru, J. A., Johnston, L. J., Negrin, R. S., Lowsky, R.
AMER SOC HEMATOLOGY.2006: 462B–463B
 - **Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity.** *48th Annual Meeting of the American-Society-of-Hematology*
Lowsky, R., Stockert-Goldstein, K., Laport, G., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Blume, K., Negrin, R., Strober, S.
AMER SOC HEMATOLOGY.2006: 182A–182A
 - **High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Shizuru, J. A., Blume, K. G., Negrin, R. S., Stockerl-Goldstein, K. E.
2006; 12 (7): 703-711
 - **Protective conditioning for acute graft-versus-host disease** *NEW ENGLAND JOURNAL OF MEDICINE*
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Hoppe, R. T., Bloch, D. A., Blume, K. G., Negrin, et al
2005; 353 (13): 1321-1331
 - **Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a case report and review of the literature** *TRANSPLANT INFECTIOUS DISEASE*
Cha, S., Johnston, L., Natkunam, Y., Brown, J.
2005; 7 (3-4): 158-161
 - **A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Nash, R. A., Johnston, L., Parker, P., McCune, P. S., Storer, B., Slattery, J. T., Furlong, T., Anasetti, C., Appelbaum, F. R., Lloid, M. E., Deeg, H. J., Kiem, H. P., Martin, et al
2005; 11 (7): 495–505
 - **A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Carpenter, P. A., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., Jerome, K. R., McCune, J. S., Storer, B., Martin, P., Appelbaum, F., Abonour, R., Westervelt, et al
2005; 11 (6): 465–71
 - **Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose** *BLOOD*
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Stuart, M. J., GRUMET, F. C., Negrin, R. S., Lowsky, R.
2005; 105 (6): 2300-2306
 - **CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies** *EXPERIMENTAL HEMATOLOGY*
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Negrin, R. S., Lowsky, R.
2005; 33 (3): 279-285

- **Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., Negrin, R. S., Chao, N. J.
2005; 11 (1): 47-55
- **Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose.** *46th Annual Meeting of the American-Society-of-Hematology*
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Stuart, M. J., Brown, J. M., GRUMET, F. C., Negrin, R. S., Lowsky, R.
AMER SOC HEMATOLOGY.2004: 56A-56A
- **Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Damon, L. E., JOHNSTON, L. J., Ries, C. A., Rugo, H. S., Case, D., Ault, K., Linker, C. A.
2004; 53 (6): 468-474
- **Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T cells and low incidences of acute GVHD and tumor relapse.** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Lowsky, R., Jones, S. D., Mitra, S., Shizuru, J. A., Laport, G. G., Stockerl-Goldstein, K., JOHNSTON, L. J., Stuart, M. J., Herzenberg, L. A., Hoppe, R. T., Blume, K. G., Negrin, R. S., Strober, et al
AMER SOC HEMATOLOGY.2003: 152A-153A
- **A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF.**
Nash, R. A., Johnston, L., Parker, P. M., Slattery, J. T., Storer, B., Furlong, T., Anasetti, C., Appelbaum, F. R., Lloid, C. M., Blume, K., Deeg, H. J., Forman, S. J., Kiem, et al
AMER SOC HEMATOLOGY.2003: 240A
- **A phase II, multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid refractory acute GVHD.**
Carpenter, P., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., Abonour, R., Westervelt, P., Dansey, R., Richard, S., Jerome, K., Corey, L., Anasetti, et al
AMER SOC HEMATOLOGY.2003: 712A
- **Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma;** *Blood*
Steven M Horwitz, Robert S Negrin, Karl G Blume, Sheila Breslin, Monic J Stuart, Keith E Stockerl-Goldstein, Laura J Johnston, Ruby M Wong, Judith A Shizuru, Sandra J Horning.
2003; 2003: 1257
- **Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial** *BLOOD*
Flowers, M. E., Parker, P. M., JOHNSTON, L. J., Matos, A. V., Storer, B., Bensinger, W. I., STORB, R., Appelbaum, F. R., Forman, S. J., Blume, K. G., Martin, P. J.
2002; 100 (2): 415-419
- **Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas.**
Horwitz, S. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Stuart, M. J., Breslin, S., Blume, K. G., Horning, S. J.
AMER SOC HEMATOLOGY.2001: 862A-862A
- **High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., Taylor, T. L., Shizuru, J. A., Hoppe, R. T., Brown, B. W., Blume, K. G., Stockerl-Goldstein, K.
2001; 7 (5): 294-301
- **Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications.**
Horwitz, S. M., Breslin, S., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Taylor, T., Brown, B. W., Blume, K. G., Horning, S. J.
AMER SOC HEMATOLOGY.2000: 384A-384A
- **High dose therapy and autologous hematopoietic cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience.**
Cao, T. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., Taylor, T. L., Shizuru, J. A., Brown, B. W., Horning, S. J., Blume, K. G., Stockerl-Goldstein, K. E.

AMER SOC HEMATOLOGY.2000: 482A-482A

- **Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation (AHCT) using the Ceprate SC stem cell concentration system for multiple myeloma (MM).**

Stockerl-Goldstein, K. E., Brown, J. M., O'Brien, R. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., Shizuru, J. A., Taylor, T. L., Blume, K. G.
AMER SOC HEMATOLOGY.1999: 608A-608A

- **So you want to build a Web site + A blueprint for museum professionals** *MUSEUM NEWS*

Johnston, L., JONESGARMIL, K.
1997; 76 (1): 41-44